Rivaroxaban Concept

subject area of

• A Replacement for Warfarin  Journal Articles
• A hybrid automated event adjudication system for clinical trials  Journal Articles
• A logical approach to surgical thromboprophylaxis  Journal Articles
• A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment  Journal Articles
• A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers  Journal Articles
• A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban  Journal Articles
• A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)  Journal Articles
• Accumulating data on rivaroxaban for venous thromboembolism in clinical practice  Journal Articles
• Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial  Journal Articles
• Acute management of bleeding in patients on novel oral anticoagulants  Journal Articles
• Advances in Antithrombotic Therapy  Journal Articles
• Advances in the management of venous thromboembolism  Journal Articles
• Advances in the management of venous thromboembolism.  Journal Articles
• Advantages and limitations of the new anticoagulants  Journal Articles
• After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding  Journal Articles
• An assay to measure levels of factor Xa inhibitors in blood and plasma  Journal Articles
• Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study  Journal Articles
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Journal Articles
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity  Journal Articles
• Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis  Journal Articles
• Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. Reply.  Journal Articles
• Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?  Journal Articles
• Antiplatelet therapy in the management of atherothrombosis: recent clinical advances  Journal Articles
• Antithrombotic Agents  Journal Articles
• Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making  Journal Articles
• Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent  Journal Articles
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Journal Articles
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Journal Articles
• Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials  Journal Articles
• Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty  Journal Articles
• Assays for Measuring Rivaroxaban: Their Suitability and Limitations  Journal Articles
• Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes  Journal Articles
• Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials  Journal Articles
• Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—A nationwide register‐based study  Journal Articles
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation  Journal Articles
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism  Journal Articles
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism  Journal Articles
• Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source  Journal Articles
• BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study  Journal Articles
• Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach  Journal Articles
• Barriers and facilitators to optimal oral anticoagulant management: a scoping review  Journal Articles
• Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty  Journal Articles
• Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin  Journal Articles
• Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness  Journal Articles
• Beyond Unfractionated Heparin and Warfarin  Journal Articles
• Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis  Journal Articles
• Bleeding and antidotes in new oral anticoagulants  Journal Articles
• Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study  Journal Articles
• Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience  Journal Articles
• Bleeding with direct oral anticoagulants vs warfarin: clinical experience  Journal Articles
• Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design  Journal Articles
• Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment  Journal Articles
• COMPASS for Vascular Surgeons  Journal Articles
• Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease  Journal Articles
• Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF  Journal Articles
• Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS  Journal Articles
• Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source  Journal Articles
• Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial  Journal Articles
• Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials  Journal Articles
• Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism  Journal Articles
• Clinical Implications of Reversal Agents for Direct Oral Anticoagulants  Journal Articles
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Journal Articles
• Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure  Journal Articles
• Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial  Journal Articles
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development  Journal Articles
• Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study  Journal Articles
• Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?  Journal Articles
• Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study  Journal Articles
• Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events  Journal Articles
• Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)  Journal Articles
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents  Journal Articles
• Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers  Journal Articles
• Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)  Journal Articles
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Journal Articles
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Journal Articles
• Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home  Journal Articles
• Design of the rivaroxaban for heparin-induced thrombocytopenia study  Journal Articles
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies  Journal Articles
• Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information  Journal Articles
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials  Journal Articles
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Journal Articles
• Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review  Journal Articles
• Direct oral anticoagulants: evidence and unresolved issues  Journal Articles
• Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis  Journal Articles
• Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence  Journal Articles
• Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances  Journal Articles
• Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial  Journal Articles
• Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis  Journal Articles
• Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism  Journal Articles
• Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis  Journal Articles
• Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state  Journal Articles
• Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism  Journal Articles
• Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism  Journal Articles
• Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1  Journal Articles
• Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants  Journal Articles
• Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease  Journal Articles
• Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD  Journal Articles
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Journal Articles
• Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial  Journal Articles
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Journal Articles
• External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry  Journal Articles
• External applicability of the COMPASS trial: the Western Denmark Heart Registry  Journal Articles
• Factor Xa and thrombin as targets for new oral anticoagulants  Journal Articles
• Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors  Journal Articles
• Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban  Journal Articles
• Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial  Journal Articles
• Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source  Journal Articles
• Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale  Journal Articles
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Journal Articles
• Global Prospective Safety Analysis of Rivaroxaban  Journal Articles
• Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease  Journal Articles
• Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis  Journal Articles
• Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy  Journal Articles
• High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source  Journal Articles
• Higher-risk APS: do we dare to DOAC?  Journal Articles
• How I treat heavy menstrual bleeding associated with anticoagulants  Journal Articles
• How I treat target-specific oral anticoagulant–associated bleeding  Journal Articles
• How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?  Journal Articles
• ISTH guidelines for antithrombotic treatment in COVID‐19  Journal Articles
• Identifying and Treating Young Patients at Risk for Cardiovascular Events  Journal Articles
• Identifying the highest risk vascular patients: Insights from the XATOA registry  Journal Articles
• Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban  Journal Articles
• Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE  Journal Articles
• Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy  Journal Articles
• Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study  Journal Articles
• In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days  Journal Articles
• Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial  Journal Articles
• Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation  Journal Articles
• Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome  Journal Articles
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants  Journal Articles
• Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy  Journal Articles
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Journal Articles
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Journal Articles
• Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation  Journal Articles
• Laboratory measurement of the direct oral anticoagulants  Journal Articles
• Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment—Reply  Journal Articles
• Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin  Journal Articles
• Less menorrhagia for women with VTE  Journal Articles
• Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials  Journal Articles
• Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial  Journal Articles
• Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels  Journal Articles
• Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD  Journal Articles
• Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.  Journal Articles
• Low-dose Rivaroxaban Plus Aspirin for the Prevention of Cardiovascular Events: an Evaluation of COMPASS  Journal Articles
• Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials  Journal Articles
• Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial  Journal Articles
• Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial  Journal Articles
• Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease  Journal Articles
• Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin  Journal Articles
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Journal Articles
• Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy  Journal Articles
• Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study  Journal Articles
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Journal Articles
• Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD  Journal Articles
• Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source  Journal Articles
• Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent  Journal Articles
• Monitoring the anticoagulant effect after a massive rivaroxaban overdose  Journal Articles
• Mortality Benefit in the Compass Trial: is It Related to Superior Statistical Power Or Better Efficacy and safety?  Journal Articles
• Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease  Journal Articles
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Journal Articles
• Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy  Journal Articles
• New Anticoagulants for Atrial Fibrillation  Journal Articles
• New Anticoagulants for Treatment of Venous Thromboembolism  Journal Articles
• New Anticoagulants for the Prevention of Thromboembolism  Journal Articles
• New Antithrombotic Drugs: Potential for Use in Oncology  Journal Articles
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Journal Articles
• New oral anticoagulants and oculoplastic surgery  Journal Articles
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Journal Articles
• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty  Journal Articles
• New oral anticoagulants in elderly patients  Journal Articles
• New oral anticoagulants: not quite there yet  Journal Articles
• New oral anticoagulants: which one should my patient use?  Journal Articles
• News at XI: moving beyond factor Xa inhibitors  Journal Articles
• Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study  Journal Articles
• Novel Oral Anticoagulants: A Focused Review for Stroke Physicians  Journal Articles
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Journal Articles
• Novel oral anticoagulants in gastroenterology practice  Journal Articles
• Novel oral anticoagulants in secondary prevention of stroke  Journal Articles
• Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants  Journal Articles
• Optimizing warfarin dosing for patients with atrial fibrillation using machine learning  Journal Articles
• Oral Anticoagulant Therapy  Journal Articles
• Oral Rivaroxaban for Symptomatic Venous Thromboembolism  Journal Articles
• Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism  Journal Articles
• Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives  Journal Articles
• Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease  Journal Articles
• Oral factor Xa inhibitors and risk of subdural hematoma  Journal Articles
• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement  Journal Articles
• Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases  Journal Articles
• Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study  Journal Articles
• Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study  Journal Articles
• Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation  Journal Articles
• Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis  Journal Articles
• Overview of the New Oral Anticoagulants  Journal Articles
• Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease  Journal Articles
• Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial  Journal Articles
• Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry  Journal Articles
• Patients with Peripheral Artery Disease in the COMPASS Trial  Journal Articles
• Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS ₂ Score: Insights From the BRAIN-AF Trial  Journal Articles
• Perioperative Management of Patients Taking Direct Oral Anticoagulants  Journal Articles
• Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial  Journal Articles
• Perioperative management of patients who are receiving a novel oral anticoagulant  Journal Articles
• Periprocedural Management of Oral Anticoagulation  Journal Articles
• Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy  Journal Articles
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Journal Articles
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Journal Articles
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery  Journal Articles
• Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients  Journal Articles
• Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study  Journal Articles
• Potential of new anticoagulants in patients with cancer  Journal Articles
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Journal Articles
• Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk  Journal Articles
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Journal Articles
• Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study  Journal Articles
• Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study  Journal Articles
• Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial  Journal Articles
• Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure  Journal Articles
• Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone  Journal Articles
• Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial  Journal Articles
• Procoagulants for management of bleeding with the new oral anticoagulants  Journal Articles
• Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study  Journal Articles
• Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study  Journal Articles
• Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors  Journal Articles
• Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)  Journal Articles
• Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery  Journal Articles
• Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial  Journal Articles
• Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS  Journal Articles
• Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation  Journal Articles
• Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism  Journal Articles
• Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD  Journal Articles
• Reply  Journal Articles
• Reply  Journal Articles
• Reply  Journal Articles
• Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban  Journal Articles
• Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation  Journal Articles
• Response to the Letter by Spurling and Colleagues  Journal Articles
• Reversal agents for current and forthcoming direct oral anticoagulants  Journal Articles
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Journal Articles
• Reversal of direct oral anticoagulants: a practical approach  Journal Articles
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Journal Articles
• Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial  Journal Articles
• Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants  Journal Articles
• Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants  Journal Articles
• Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study  Journal Articles
• Risk of recurrent venous thromboembolism according to baseline risk factor profiles  Journal Articles
• Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis  Journal Articles
• Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial  Journal Articles
• Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD  Journal Articles
• Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial  Journal Articles
• Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial  Journal Articles
• Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction  Journal Articles
• Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease  Journal Articles
• Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease  Journal Articles
• Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization  Journal Articles
• Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios  Journal Articles
• Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation  Journal Articles
• Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization  Journal Articles
• Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro  Journal Articles
• Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial  Journal Articles
• Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography  Journal Articles
• Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial  Journal Articles
• Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions  Journal Articles
• Rivaroxaban for Patients with Intermittent Claudication.  Journal Articles
• Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial  Journal Articles
• Rivaroxaban for Prevention and Treatment of Venous Thromboembolism  Journal Articles
• Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline  Journal Articles
• Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source  Journal Articles
• Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice  Journal Articles
• Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness  Journal Articles
• Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer  Journal Articles
• Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older  Journal Articles
• Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial  Journal Articles
• Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease  Journal Articles
• Rivaroxaban for the prevention and treatment of venous thromboembolism  Journal Articles
• Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty  Journal Articles
• Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies  Journal Articles
• Rivaroxaban for treatment of HIT: A riveting first experience  Journal Articles
• Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation  Journal Articles
• Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study  Journal Articles
• Rivaroxaban in Orthopedic Surgery — A Change of Paradigm?  Journal Articles
• Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment  Journal Articles
• Rivaroxaban in Peripheral Artery Disease after Revascularization  Journal Articles
• Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation  Journal Articles
• Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation  Journal Articles
• Rivaroxaban in Stable Cardiovascular Disease  Journal Articles
• Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits  Journal Articles
• Rivaroxaban in treatment refractory heparin-induced thrombocytopenia  Journal Articles
• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism  Journal Articles
• Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial  Journal Articles
• Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition  Journal Articles
• Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers  Journal Articles
• Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty  Journal Articles
• Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy  Journal Articles
• Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial  Journal Articles
• Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial  Journal Articles
• Rivaroxaban versus enoxaparin after total knee arthroplasty  Journal Articles
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial  Journal Articles
• Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study  Journal Articles
• Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial  Journal Articles
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease  Journal Articles
• Rivaroxaban with or without aspirin for prevention of cardiovascular disease  Journal Articles
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial  Journal Articles
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  Journal Articles
• Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion  Journal Articles
• Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease  Journal Articles
• Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study  Journal Articles
• Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)  Journal Articles
• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin  Journal Articles
• Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist  Journal Articles
• Selective factor Xa inhibition for thromboprophylaxis  Journal Articles
• Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustment  Journal Articles
• Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD  Journal Articles
• Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial  Journal Articles
• Stroke Outcomes in the COMPASS Trial  Journal Articles
• Stroke Prevention in Atrial Fibrillation  Journal Articles
• Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification?  Journal Articles
• Stroke prevention in atrial fibrillation: Closing the gap  Journal Articles
• Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis  Journal Articles
• Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease  Journal Articles
• TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol  Journal Articles
• The COMPASS Trial  Journal Articles
• The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective  Journal Articles
• The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis  Journal Articles
• The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population  Journal Articles
• The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation  Journal Articles
• The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE  Journal Articles
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Journal Articles
• The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial  Journal Articles
• The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale  Journal Articles
• The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation  Journal Articles
• The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial  Journal Articles
• The effects of rivaroxaban on the complications of surgery after total hip or knee replacement  Journal Articles
• The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study  Journal Articles
• The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial  Journal Articles
• The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients  Journal Articles
• The top 4 advances in antithrombotic care in the last year  Journal Articles
• Thromboprophylaxis after knee arthroscopy does not decrease the risk of deep vein thrombosis: a network meta-analysis  Journal Articles
• Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials  Journal Articles
• Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial  Journal Articles
• Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial  Journal Articles
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Journal Articles
• Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies  Journal Articles
• Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)  Journal Articles
• Treatment of venous thromboembolism with dabigatran  Journal Articles
• Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014  Journal Articles
• Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism  Journal Articles
• Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study  Journal Articles
• Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD  Conferences
• Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study  Journal Articles
• Venous thromboembolism management: where do novel anticoagulants fit?  Journal Articles
• Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials  Journal Articles
• XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America  Journal Articles
• XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation  Journal Articles
• XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation  Journal Articles
• Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both  Journal Articles